GSK2110183 analog 1 is primarily explored in the field of medicinal chemistry and drug development as an analog of the AKT kinase inhibitor GSK2110183 (Afuresertib). Its applications are centered around its potential as a therapeutic agent, particularly in targeting specific cellular pathways involved in disease progression, such as the PI3K/AKT/mTOR pathway. The compound is studied for its ability to inhibit key kinases or proteins that play a critical role in conditions such as cancer, autoimmune disorders, or inflammatory diseases. Researchers focus on its efficacy and selectivity in preclinical models to assess its viability as a lead compound for further optimization. Additionally, it is utilized in biochemical assays to understand molecular interactions and mechanisms of action, contributing to the broader knowledge of targeted therapies. Its development is part of ongoing efforts to discover novel treatments with improved safety and efficacy profiles.